Clinical Trial Detail

NCT ID NCT02943473
Title Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Icahn School of Medicine at Mount Sinai
Indications

multiple myeloma

Therapies

Ibrutinib

Age Groups: senior adult

No variant requirements are available.